The ITTACA study homepage

The Immunotherapy TimeTeller for Advanced lung CAncer Study (ITTACA) aims to determine if a recently developed method to determine the circadian clock in biosamples from patients is useful and feasible in a cohort of lung cancer patients treated with immune-checkpoint inhibitors.

Collaborators

Dr Seline Ismail-Sutton (Trial PI)

Dr Pasquale Innominato (co-PI)

Dr Robert Dallmann (Collaborator)